HIV-1 subtypes and drug resistance profiles in a cohort of heterosexual patients in Istanbul, Turkey

[1]  Guangdi Li,et al.  HIV-1 Gag C-terminal amino acid substitutions emerging under selective pressure of protease inhibitors in patient populations infected with different HIV-1 subtypes , 2014, Retrovirology.

[2]  M. Bickel,et al.  Improved virological and immunological efficacy of resistance-guided switch in antiretroviral therapy: a Frankfurt HIV cohort analysis , 2014, Medical Microbiology and Immunology.

[3]  R. Kaiser,et al.  Determination of Drug Resistance and Virus Typology in HIV-1-Positive Pediatric Patients in Istanbul, Turkey , 2014, Intervirology.

[4]  R. Kaiser,et al.  HIV in Turkey, a country bridging the Islamic world and Europe. , 2014, Journal of infection and public health.

[5]  C. Passaes,et al.  HIV cure research: advances and prospects. , 2014, Virology.

[6]  R. Kaiser,et al.  Molecular epidemiology of HIV in a cohort of men having sex with men from Istanbul , 2013, Medical Microbiology and Immunology.

[7]  R. Kaiser,et al.  Mutational patterns in the frameshift-regulating site of HIV-1 selected by protease inhibitors , 2012, Medical Microbiology and Immunology.

[8]  R. Shafer,et al.  Standardized Comparison of the Relative Impacts of HIV-1 Reverse Transcriptase (RT) Mutations on Nucleoside RT Inhibitor Susceptibility , 2012, Antimicrobial Agents and Chemotherapy.

[9]  K. White,et al.  The HIV-1 Reverse Transcriptase M184I Mutation Enhances the E138K-Associated Resistance to Rilpivirine and Decreases Viral Fitness , 2012, Journal of acquired immune deficiency syndromes.

[10]  D. Kuritzkes.  Drug resistance in HIV-1. , 2011, Current opinion in virology.

[11]  Thomas Lengauer,et al.  Prediction of HIV-1 coreceptor usage (tropism) by sequence analysis using a genotypic approach. , 2011, Journal of visualized experiments : JoVE.

[12]  J. Vingerhoets,et al.  Effect of Mutations at Position E138 in HIV-1 Reverse Transcriptase on Phenotypic Susceptibility and Virologic Response to Etravirine , 2011, Journal of acquired immune deficiency syndromes.

[13]  B. Torbett,et al.  Accessory mutations maintain stability in drug-resistant HIV-1 protease. , 2011, Journal of molecular biology.

[14]  David Dunn,et al.  Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. , 2011, The Lancet. Infectious diseases.

[15]  Thomas Lengauer,et al.  HIV prevalence and route of transmission in Turkish immigrants living in North-Rhine Westphalia, Germany , 2011, Medical Microbiology and Immunology.

[16]  M. Poljak,et al.  European recommendations for the clinical use of HIV drug resistance testing: 2011 update. , 2011, AIDS reviews.

[17]  M. de Béthune,et al.  Characterization of genotypic and phenotypic changes in HIV-1-infected patients with virologic failure on an etravirine-containing regimen in the DUET-1 and DUET-2 clinical studies. , 2010, AIDS research and human retroviruses.

[18]  Susan P. Holmes,et al.  Constrained patterns of covariation and clustering of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations , 2010, The Journal of antimicrobial chemotherapy.

[19]  Dirk Jochmans,et al.  TMC278, a Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI), Active against Wild-Type and NNRTI-Resistant HIV-1 , 2009, Antimicrobial Agents and Chemotherapy.

[20]  V. Calvez,et al.  Antiretroviral combinations implicated in emergence of the L74I and L74V resistance mutations in HIV-1-infected patients , 2009, AIDS.

[21]  L. Bacheler,et al.  Prediction of HIV-1 drug susceptibility phenotype from the viral genotype using linear regression modeling. , 2007, Journal of virological methods.

[22]  Rolf Kaiser,et al.  Compensatory Mutations at the HIV Cleavage Sites P7/P1 and P1/P6-Gag in Therapy-Naive and Therapy-Experienced Patients , 2006, Antiviral therapy.

[23]  R. Kaiser,et al.  Primary HIV Drug Resistance and Efficacy of First-Line Antiretroviral Therapy Guided by Resistance Testing , 2006, Journal of acquired immune deficiency syndromes.

[24]  R. Pauwels,et al.  TMC125 Displays a High Genetic Barrier to the Development of Resistance: Evidence from In Vitro Selection Experiments , 2005, Journal of Virology.

[25]  Matthew J. Gonzales,et al.  Distribution of Human Immunodeficiency Virus Type 1 Protease and Reverse Transcriptase Mutation Patterns in 4,183 Persons Undergoing Genotypic Resistance Testing , 2004, Antimicrobial Agents and Chemotherapy.

[26]  M. Wainberg,et al.  Negative effect of the M184V mutation in HIV-1 reverse transcriptase on initiation of viral DNA synthesis. , 2003, Virology.

[27]  M. Segondy,et al.  Prevalence of the mutational pattern E44D/A and/or V118I in the reverse transcriptase (RT) gene of HIV‐1 in relation to treatment with nucleoside analogue RT inhibitors , 2002, Journal of medical virology.

[28]  W. Heneine,et al.  Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[29]  T. Merigan,et al.  Variants Other than Aspartic Acid at Codon 69 of the Human Immunodeficiency Virus Type 1 Reverse Transcriptase Gene Affect Susceptibility to Nucleoside Analogs , 2001, Antimicrobial Agents and Chemotherapy.

[30]  V. Trouplin,et al.  Retracing the Evolutionary Pathways of Human Immunodeficiency Virus Type 1 Resistance to Protease Inhibitors: Virus Fitness in the Absence and in the Presence of Drug , 2000, Journal of Virology.

[31]  S. Hammer,et al.  Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine , 2000, AIDS.

[32]  B. Larder,et al.  Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[33]  F. Tabak,et al.  [Molecular Epidemiological Analysis of HIV-1 pol Gene Sequences Isolated in Istanbul, Turkey]. , 2013, Mikrobiyoloji bulteni.

[34]  A. Willke,et al.  HIV-1 subtypes and primary antiretroviral resistance mutations in antiretroviral therapy naive HIV-1 infected individuals in Turkey. , 2013, Japanese journal of infectious diseases.

[35]  R. Kaiser,et al.  Prevalence of C-terminal gag cleavage site mutations in HIV from therapy-naïve patients. , 2009, The Journal of infection.

[36]  Bradley J. Betts,et al.  Human immunodeficiency virus reverse transcriptase and protease sequence database. , 2003, Nucleic acids research.